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correlated. Eighteen animals have been studied have been studies to assess the rate of
depreciation of the drugs over 6 months’ duration.
Results: Whereas specimens of the 2 S. aureus-treated unbonded grafts had high bacterial
counts (6.25106 and 1.38107 CFU/graft), specimens of the 2 S. aureus-treated bonded
grafts showed no bacterial growth. Bacterial growth in the 2 control pigs’ grafts (1.8103
and 7.27103 CFU/graft) reflected direct accidental perioperative bacterial contamina-
tion; the organisms isolated were not S. aureus (S. cohnii spp urealyticus and S.
chromogenes). The histopathologic and clinical data confirmed the microbiological
findings. Only pigs that received unbonded grafts showed histopathologic evidence of
perigraft abscess.
Conclusions: The quantitative results of our studies showed that bonding 3 antimicrobial
agents to aortic grafts prevented aortic graft infection by synergistically prolonging
antistaphylococcal activity. After the safety and preventive effect of this graft have been
further assessed, its use may be recommended for the in situ replacement of infected grafts
and possibly for routine primary cases, especially in immunocompromised patients,
patients with a hostile abdomen, and patients undergoing redo procedures.
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Background: This study reports the 2-year outcomes of the United States (US)
regulatory trial of the Endurant Stent Graft System (Medtronic Vascular, Santa Rosa, CA)
for the treatment of abdominal aortic aneurysms (AAA).
Methods: This was a prospective, single arm, multicenter trial conducted at 26 sites in the
US. From April 2008 to May 2009, 150 patients with AAA were treated with the
Endurant bifurcated stent graft. The main inclusion criteria were an AAA diameter 5
cm, proximal neck length 10 mm, bilateral iliac fixation length 15 mm, and a neck
angulation of60 degrees. The primary safety endpoint was freedom from major adverse
events at 30 days. The primary effectiveness endpoint was successful aneurysm treatment
at 12 months. Two years results are site reported.
Results: One hundred forty-nine patients (99.3%) had a successful implantation of the
Endurant stent graft. The one failure was due to the inability to cannulate the contralateral
gate. Patients within this trial were mostly male (91.3%), with a mean age of 73.1 and who
had significant comorbidities. Mean estimated blood loss was 185 mL (range, 0-1450 ml),
with one patient requiring a blood transfusion. The average hospital stay was 2.1 days.
Through the 24 month follow up, there were no ruptures, migrations or conversions to
open repair. The technical observations found no graft kinking or twisting, and no
fractures. A total of two (1.5%) stent graft occlusions were observed at the 2 year
follow-up. There were no type I or type III endoleaks observed at 24 months. Aneurysm
sac diameter decreased greater than 5mm occurred in 60.8% of patients and remained
stable in 36.9% of patients. There were only three patients (2.3%) that had an increase sac
of more than 5mm. There were no aneurysm related deaths (100% Freedom from ARM)
through two years.
Conclusions: The two year results of this pivotal trial continue to show that the Endurant
Stent Graft is a safe, durable, and effective device for the treatment of abdominal aortic
aneurysms.
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Background: Improvements in technique and devices promise improved outcomes
following endovascular repair of aneurysms of the descending thoracic aortic. This
mid-term report provides an update to the VALOR II trial results.
Methods: VALOR II is a prospective, multicenter, observational study of endovascular
treatment with the Valiant thoracic stent graft (Medtronic Endovascular Therapies, Santa
Rosa, Calif) in patients with descending thoracic aortic aneurysms (TAA) of degenerative
etiology.
Results: VALOR II enrolled 160 patients between December 2006 to September 2009
and 1-year results have been previously reported. In this update, follow-up was available
on 72% of patients through 3 years. One additional aneurysm-related death occurred after
1 year. One conversion to surgery was performed at 3 years in a patient who had
continued aneurysm expansion in the absence of any observable endoleak. Seven
secondary stent graft procedures were performed in 6 patients; 1 in the first 30 days, 3 after
1 year and 3 after 2 years. Freedom from secondary stent graft procedures was 94.9% at
3 years (95% CI: 88.8%-97.7%), which compared favorably with the earlier VALOR trial
(85.1% at 3 years; 95% CI: 78.5%-89.8%), a study of the Talent thoracic stent graft with
similar objectives and inclusion criteria. There was no type I or III endoleak reported at
2 or 3 years.
Conclusions: Mid-term results with the Valiant thoracic stent graft are acceptable and
compare favorably to an older generation device implanted in an earlier series of similar
patients. Long term results are needed to confirm this positive trend.
TCT-128
Disruptive Endovascular Technology with Multilayer Flow Modulator Stents
(MFM) as a Therapeutic Option in the Management of Thoraco-abdominal
Aortic Aneurysms. Early results from MFM Registry.
Sherif Sultan1, Niamh Hynes2
1Western Vascular Institute, Galway, — Please Select —, 2Western Vascular
Institute, Galway, Ireland
Background: Out of 172 cases implanted worldwide we present the first 26 cases that
were scrutinized. All were Crawford thoraco-abdomial AAA. 75% were male with
median age of 73. Mean aneurysm diameter was 67mm with mean length of 167mm.
79.7% were ASA IV E. 62 % were redo after previous TEVAR.
Methods: Primary Endpoints are Freedom from Rupture and Aneurysm-related Death,
Aneurysm Sac and Lumen Volume Modulation, Patency of Visceral Branches, and
Freedom from Stroke and Paraplegia. Secondary Endpoints were technical success and
all-cause mortality. Finite Element Analyses was achieved on aortic sac pressure, shear
stress, wall displacement and blood flow velocities. All stents were deployed to their
intended target. No Aneurysm-related death occurred within 18 Months. No peri-
operative Visceral or Renal insult occurred. There were no Cerebro-vascular accidents,
paraplegia or loss of visceral branches patency. Two patients required reintervention
because of device foreshortening.
Results: At 6 months there was decline in average total sac volume, thrombus volume
and average diameter. Mean sac volume shrunk by 8% with lumen volume reduction of
14%. Average thrombus volume increased but thrombus to lumen ratio decreased by
23%. Finite Element Analysis post MFM documented dampening of wall displacement
by 80% with immediate depressurization of the aortic sac and dissipation of the maximum
pressure zone. There was 55% immediate reduction in Wall Stress.
Conclusions: MFM carries no risk of critical shuttering or loss of native side branches.
MFM offers immense promise for resolution of complex thoraco-abdominal aneurysms.
A Global MFM Registry is required and long-term follow-up is mandatory.
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Background: Out of 683 AAA operated upon, 120 patients presented with RAAA over
12 years, 42 had REVAR and 78 had OR.
Methods: Parallel Group comparison.
Results: Mean length of ICU was halved with REVAR VS OR (P0.008). Blood
product requirements were 60% less in REVAR (P0.0001). The Risk of ARDS and
cardiac events were doubled if OR were performed .However there were no statistical
significance in acute renal injury. Mean length of hospital stay was 7	/3 days for
REVAR , and 12	/6 for OR (P0.042).Thirty day mortality was 16% for REVAR vs
32% for OR ( P0.001). Total Emergency mortality rate decreased from 64% to 28.2%.
we attributed the Low Mortality Rate of 16%for REVAR Vs 32%in OR was due to
introduction of an REVAR Programme which constitutes screening for prevention with
early intervention and REVAR for rupture which has an absolute perioperative mortality
reduction of 49% over OR. 5 years Survival of Patients with RAAA were 75% REVAR
vs. 60% OR (p0.0205). During 20th century 95% of all AAA were done surgically.
However during 21st century 80% of AAA is done endovascularly. Mean Annual number
of OR dropped (P0.845) however Mean Annual number of EVARs had rocketed
(P0.006) . Overall number of AAA repairs has increased by 65% over twelve year’s
period but the absolute number of RAAA had declined by 24%.
Conclusions: Para-Millennium and Contemporary Trends in AAA Management had
shown Increased in Elective EVAR which increased the mortality advantage in favour of
REVAR and it should be the Gold standard for RAAA.
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Background: EVAR affords more propitious peri-operative and long-term survival than
Open Surgical Repair (OSR). However, up to 70% of AAAs are anatomically incompat-
ible with EVAR.
Methods: We aim to gauge the feasibility of applying commercially-available endografts
to pararenal aneurysms compared with OSR. Primary endpoints were aneurysm-related
survival and cost per Quality-Adjusted–Life-Years (QALY). From 2002-2009, 1868
patients with pararenal AAA were investigated. 118 had intervention and were described
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AM www.jacc.tctabstracts2012.com







by consultant radiologists as ’unsuitable for EVAR’. 66 had OSR and 52 had Pararenal
EVAR (PEVAR).
Results: PEVAR patients were older (74.3yrs vs. 70.8 yrs, p0.014) with higher mean
SVS co-morbidity severity scores (p0.0001). All procedures were within 14 days of
diagnosis. Mean aneurysm diameter was larger in OSR (OSR 6.6cm vs. PEVAR 5.9cm,
p0.010). For PEVAR 83% of endografts were 34mm/36mm. 3-year aneurysm-related
survival was significantly higher with PEVAR (100% vs. OSR (92.4%	/4.37%),
p0.045). PEVAR provided an incremental cost-effectiveness ratio of €129,586 saved
per QALY gained. 3-year freedom from secondary intervention (PEVAR 83.4% vs OSR
95.5%, P0.301) and all-cause survival (PEVAR 57.1% vs. OSR 84.8%, p0.195) were
similar. 30-day morbidity halved with PEVAR (15% vs. 30%, p0.059). Length of
hospital stay (p0.0007) was lower and number of patients fit for discharge to their home
(p0.006) higher with PEVAR.
Conclusions: PEVAR granted our patients longer Q-TWiST and Superior Freedom from
MACE up to three years. Despite 3-year survival rate of 57%, PEVAR is cost-effective
and offered as Endo-bailing for patients living on borrowed time, abolishes the socio-
economic catastrophe of managing a rupture PAAA.
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Background: The risk of clinical apparent, periprocedural stroke after thoracic endovascular
aortic repair (TEVAR) ranges between 2 and 6% and has been associated with increased
postoperative mortality. Stroke after TEVAR is thought to be related to multiple emboli, which
are dislodged during manipulation of guidewires, catheters and large-bore delivery devices in
the diseased aortic arch. Such emboli may also account for clinically silent cerebral ischemia.
However, the rate of silent cerebral ischemia in the setting of TEVAR is yet unknown, but may
be even higher than the rate of clinical apparent neurological events.
Methods: Twenty patients (12 male, 8 female) who underwent TEVAR were included
into this descriptive study; exclusion criteria were a history of stroke, carotid artery
disease, renal failure and contraindications for magnetic resonance imaging (MRI).
Periprocedural apparent and silent cerebral ischemia was assessed by neurological testing
and serial cerebral diffusion-weighted MRI (DW-MRI) at baseline and within the first 10
days (mean: 4.9 days) post procedure.
Results: TEVAR was successful in all patients without immediate clinically apparent
neurological deficits. Post-interventional cerebral DW-MRI detected a total of 33 new foci
of restricted diffusion in 13 of the 20 patients (65%). Lesions were usually multiple (1-6
lesions per patient) and ranged in size between 15 mm3 and 585 mm3. 17 lesions were
found in the left middle cerebral artery and PICA territory, 10 lesions in the right middle
cerebral artery and PICA territory. Overstenting of the left-subclavian artery was
performed in 9 cases, but was not associated with lateralization of lesions. There were no
additional apparent neurological events during the in-hospital period.
Conclusions: TEVAR resulted in a high incidence of new foci of restricted diffusion on
cerebral DW-MRI in a pattern suggestive for periprocedural embolization. Although even
multiple lesions per patients were found, these lesions were not associated with apparent
neurological deficits during the in-hospital period. Further developments in TEVAR
should be directed towards reducing the risk of periprocedural cerebral embolization.
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Background: In the era of drug eluting stent, progression of non-culprit coronary lesion
emerged as a new therapeutic target of coronary artery disease. We aimed to clarify the
prognostic factors for the progression of non-culprit coronary lesion after percutaneous
coronary intervention (PCI).
Methods: We retrospectively examined 401 patients who underwent PCI during
February 2010 to January 2011 in our institute. Among them, 275 patients were
performed follow-up coronary angiography (CAG) 6-12 months after PCI. Patients with
target lesion revascularization (n39) were excluded. Finally, total of 236 patients were
included in this study. Progression of non-culprit lesion was defined as clinically driven
PCI because of the development of coronary lesion which was not significant at initial PCI
but significant at follow-up CAG, and was associated with ischemic symptom and/or
abnormal results of functional study.
Results: Thirty three patients (14%) underwent additional clinically driven PCI to treat
non-culprit coronary lesions. There was no difference in background clinical characteristics
between patient with or without progression of non-culprit lesion PCI. Prevalence of chronic
kidney disease (CKD) (61% vs. 31%, p0.001) and multi-vessel disease (MVD) (55% vs.
35%, p0.027) were significantly higher and statin use (61% vs. 72%, p0.187) was tended
to be lower in patients with non-culprit lesion PCI than those without. Brachial-ankle pulse
wave velocity (baPWV) was significantly higher in patients with non-culprit lesion PCI than
those without (1838371 vs. 1589313cm/s, p0.001). High density lipoprotein cholesterol
level at follow-up CAG was tended to be lower in patients with non-culprit lesion PCI than
those without (5415 vs. 5816mg/dL, p0.147). Multivariate analysis showed that higher
baPWV, CKD, MVD, and lower HDL at follow-up CAG were independent determinants for
progression of non-culprit coronary lesion.
Conclusions: In conclusion, higher baPWV, CKD, MVD, and lower HDL at follow-up
CAG were independent determinants of non-culprit coronary lesion PCI, suggesting
important prognostic role of arterial stiffness and impaired renal function in the
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Background: Recent insurance-based observational data indicate that the ratio of
contrast volume (CV) use to calculated creatinine clearance predicts acute kidney injury
(AKI). Whether these findings will be observed in other populations, is uncertain.
Methods: 11,986 CATH and PCI procedures were performed at a single center (Wake
Forest Baptist Medical Center) between January 2007 and December 2011 and were
evaluated for AKI post-procedure. A contrast minimization strategy including automated
contrast injection was used in all patients. Procedures with missing pre- or post-creatinine
or renal failure with dialysis were excluded (n4,117). Glomerular filtration rate was
estimated (eGFR).
Results: High risk baseline characteristics were significantly more prevalent with AKI
(n430) compared to no AKI (n7,439), including CHF, diabetes, prior renal failure,
acute MI, and elevated baseline creatinine. Per institutional standard of practice CV use
was 20 mL lower per procedure for those with AKI (p0.001), but CV/eGFR was 30%
higher for those with AKI (p0.001). After multivariable adjustment, CV/eGFR
remained a significant independent predictor of AKI, with CV/eGFR 3.0 having 2.18
(1.59-3.00) increased odds of AKI vs. CV/eGFR 3.0 (see Figure).
Conclusions: In this prospective observational registry CV/eGFR was independently
predictive of AKI, with a ratio 3.0 associated with two-fold greater risk of AKI. These
data provide strong support for the use of this metric as a risk-reduction method for AKI
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